18F-FDG PET/CT与PET/MRI在胰腺导管腺癌中的作用
综述探讨18F-FDG PET/CT与PET/MRI在胰腺导管腺癌中的应用,指出PET/CT在诊断、初始分期、疗效评估、鉴别复发与治疗后纤维化及放疗计划方面可能有帮助,并可能因对原判可手术患者重新分期而具成本效益;PET/MRI作为新兴混合功能成像技术具有潜在应用价值,但两种模态在PDAC中的作用仍需进一步研究。
要点
- PET/CT在PDAC的诊断、初始分期、疗效评估、复发与治疗后纤维化鉴别及放疗计划中可能有帮助。
- PET/CT可能因对原判可手术患者重新分期而具有成本效益。
- PET/MRI具有同步采集、辐射剂量较低、软组织对比优越及多参数成像等优势,在PDAC中的应用正在研究中。
核心结论
- PET/CT在PDAC管理中的角色仍在演变且目前尚未很好确立,研究显示其在某些场景下可能较CT或MRI等解剖成像有额外获益;PET/MRI是混合功能成像的新进展,在PDAC中具有潜在应用价值,但两种模态均需进一步研究以更好理解其在PDAC中的作用。
研究设计与样本
- 综述,未报告系统检索范围与纳入文献数量;讨论18F-FDG PET/CT与PET/MRI在胰腺导管腺癌中的应用。
临床应用与阅片要点
- 作者指出PET/CT可能用于PDAC的诊断、初始分期、治疗反应评估、鉴别复发肿瘤与治疗后纤维化以及放疗计划;PET/MRI的优势包括同步采集改善融合图像配准、较低辐射剂量、优越的软组织对比以及多参数成像的可及性;研究正在进行以评估PET/MRI在PDAC中的效用(包括初始分期和治疗反应评估)并确定将从PET/MRI获益的患者亚组。
局限性
- PET/CT在PDAC中的作用仍在不断演变,目前尚未很好确立。
- 需要进一步研究PET/CT和PET/MRI以更好理解这些模态在PDAC中的作用。
- 研究正在进行以评估PET/MRI在PDAC中的效用并确定将从PET/MRI获益的患者亚组。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
英文原文(摘要)· 点击展开
Pancreatic ductal adenocarcinoma (PDAC) remains a difficult disease to treat and continues to portend a poor prognosis, as most patients are unresectable at diagnosis. 18F-fluorodeoxyglucose (FDG) positron emission tomography (PET) combined with CT (PET/CT) has been a cornerstone in oncological imaging of different cancers; however, the role of PET/CT in PDAC is continually evolving and currently not well established. Studies have shown the potential of PET/CT in guiding the management of patients with PDAC, with possible added benefit over anatomic imaging with CT or MRI in certain scenarios. PET/CT may be useful in diagnosis, initial staging, treatment response assessment, differentiation of recurrent tumor from post-treatment fibrosis, and radiotherapy planning. Additionally, PET/CT may be a cost-effective modality due to upstaging of patients originally deemed as surgical candidates. Recently, the advent of simultaneous PET/MRI represents an exciting advancement in hybrid functional imaging with potential applications in the imaging of PDAC. The advantages of PET/MRI include simultaneous acquisition to improve registration of fusion images, lower radiation dose, superior soft tissue contrast, and availability of multiparametric imaging. Studies are underway to evaluate the utility of PET/MRI in PDAC, including in initial staging and treatment response assessment and to determine the subgroup of patients that will benefit from PET/MRI. Further studies are warranted in both PET/CR and PET/MRI to better understand the role of these modalities in PDAC.
引用
- Yeh R, Dercle L, Garg I, et al. The Role of 18F-FDG PET/CT and PET/MRI in Pancreatic Ductal Adenocarcinoma. Abdom Radiol (NY). 2018. PMID: 29143875. doi:10.1007/s00261-017-1374-2
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。